Promising survival in patients with recurrent non-small cell lung cancer treated with docetaxel and gemcitabine in combination as second-line therapy

Journal of Thoracic Oncology

Volumn 3, Issue 9, 2008, Pages 1032-1038

  Huang, Chao Hui ^a,e   Millenson, Michael M ^b   Sherman, Eric J ^c   Borghaei, Hossein ^b   Mintzer, David M ^d   Cohen, Roger B ^b   Staddon, Arthur P ^d   Seldomridge, Judi ^b   Treat, Ocn Joseph ^b   Tuttle, Holly ^b   Ruth, Karen J ^b   Langer, Corey J ^b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b FOX CHASE CANCER CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d Pennsylvania Onc Hem Associates (POHA)   (United States)

^e UNIVERSITY OF KANSAS CANCER CENTER   (United States)

Author keywords

Docetaxel; Gemcitabine; Recurrent lung cancer; Second line therapy

Indexed keywords

3 (4 BROMO 2,6 DIFLUOROBENZYLOXY) 5 [3 [4 (1 PYRROLIDINYL)BUTYL]UREIDO] 4 ISOTHIAZOLECARBOXAMIDE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; ETOPOSIDE; GEFITINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; VASCULOTROPIN; VASCULOTROPIN ANTIBODY; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE ESCALATION; DRUG FATALITY; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; INFECTION; LEG EDEMA; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; ORTHOSTATIC HYPOTENSION; OVERALL SURVIVAL; PAIN; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RASH; RECURRENT CANCER; SIDE EFFECT; SKIN TOXICITY; SYNCOPE; TACHYCARDIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VOMITING; CANCER STAGING; LUNG TUMOR; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SALVAGE THERAPY; SURVIVAL RATE; TAXOIDS;

EID: 58149135010     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31818307c2     Document Type: Article

References (34)

1. Schiller JH, Harrington D, Belani CP, et al. The Eastern Cooperative Oncology Group comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98.
2. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
3. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III Trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000;18:2354-2362.
4. Di Maio M, Perrone F, Chiodini P, et al. Individual patient data meta-analysis of docetaxel administered once every 3 weeks compared with once every week second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol 2007;25:1377-1382.
5. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003;21:3016-3024.
6. Anderson H, Lund B, Bach F, Thatcher N, Walling J, Hansen HH. Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1821-1826.
7. Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small-cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-1540.
8. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-130.
9. Matsui K, Hirashima T, Nitta T, et al. A phase I/II study comparing regimen schedules of gemcitabine and docetaxel in Japanese patients with stage IIIB/IV non-small cell lung cancer. Jpn J Clin Oncol 2005;35:181-187.
10. Hirsh V, Whittom R, Desjardins P, et al. Docetaxel and Gemcitabine administered on days 1 and 8 for metastatic non-small cell lung carcinoma (NSCLC): a phase II multicenter trial. Lung Cancer 2004;46:113-118.
11. Israel V, Tagawa ST, Snyder T, Jeffers S, Raghavan D. Phase I/II of gemcitabine plus docetaxel in advanced non small cell lung cancer (NSCLC). Invest New Drugs 2004;22:291-297.
12. Spiridonidis CH, Laufman LR. Docetaxel and gemcitabine combination in chemotherapy-pretreated non small cell lung cancer. Clin Lung Cancer 2000;1(suppl 1):S20-S23.
13. Skarlos DV, Dimopoulos AM, Kosmidis P, et al. Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group. Lung Cancer 2003;41:107-111.
14. Rebattu P, Quantin X, Ardiet C, et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 2001;33:277-287.
15. Georgoulias V, Samonis G, Papadakis E, et al. Comparison of docetaxel/ cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung Cancer 2001;34(suppl 4):S47-S51.
16. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 1998;3:237-252.
17. Pellegrini C, Falleni M, Marchetti A, et al. HER-2/Neu alterations in non-small cell lung cancer a comprehensive evaluation by real time reverse transcription-PCR, fluorescence in situ hybridization, and immunohistochemistry. Clin Cancer Res 2003;9:3645-3652.
18. Han H, Landreneau RJ, Santucci TS, et al. Prognostic value of immunohistochemical expressions of p53, HER-2/neu, and bcl-2 in stage I non-small-cell lung cancer. Hum Pathol 2002;33:105-110.
19. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-792.
20. Langer CJ, Stephenson P, Thor A, Vangel M, Johnson DH; Eastern Cooperative Oncology Group Study 2598. Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group Study 2598. J Clin Oncol 2004;22:1180 -1187.
21. Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. Ann Oncol 2004;15:19-27.
22. Syrigos KN, Dannos I, Dionellis G, et al. Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study. Anticancer Res 2005;25:3489-3493.
23. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. Ann Oncol 2005;16:602-610. Epub 2005 Mar 1.
24. Rocha Lima CM, Rizvi NA, Zhang C, et al. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Ann Oncol 2004;15:410-418.
25. Kosmas C, Tsavaris N, Vadiaka M, et al. Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens. Cancer 2001;92:2902-2910.
26. Kalmadi S, McNeill G, Davis M, Peereboom D, Adelstein D, Mekhail T. Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Med Oncol 2006;23:507-513.
27. Neubauer MA, Garfield DH, Kuerfler PR, et al. Results of a phase II multicenter trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer. Lung Cancer 2005;47:121-127.
28. Hainsworth JD, Erland JB, Barton JH, et al. Combination treatment with weekly docetaxel and gemcitabine for advanced non-small-cell lung cancer in elderly patients and patients with poor performance status: results of a Minnie Pearl Cancer Research Network phase II trial. Clin Lung Cancer 2003;5:33-38.
29. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. New Engl J Med 2005;353:123-132.
30. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589 -1597.
31. Herbst RS, O'Neill VJ, Fehrenbacher L, et al. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non-small-cell lung cancer. J Clin Oncol 2007;25:4743- 4750.
32. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006;7:719 -727.
33. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
34. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;352:2589-2597.